Objective: To analyze data available in the literature regarding a possible prognostic value of the platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) in prostate cancer (PCa) patients stratif...Objective: To analyze data available in the literature regarding a possible prognostic value of the platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) in prostate cancer (PCa) patients stratified in non-metastatic and metastatic diseases.Methods: A literature search process was performed following the Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines. In our meta-analysis, the pooled event rate estimated and the pooled hazard ratio were calculated using a random effect model.Results: Forty-two articles were selected for our analysis. The pooled risk difference for non-organ confined PCa between high and low NLR cases was 0.06 (95% confidence interval [CI]: −0.03-0.15) and between high and low PLR cases increased to 0.30 (95% CI: 0.16-0.43). In non-metastatic PCa cases, the pooled hazard ratio for overall mortality between high and low NLR was 1.33 (95% CI: 0.78-1.88) and between high and low PLR was 1.47 (95% CI: 0.91-2.03), whereas in metastatic PCa cases, between high and low NLR was 1.79 (95% CI: 1.44-2.13) and between high and low PLR was 1.05 (95% CI: 0.87-1.24).Conclusion: The prognostic values of NLR and PLR in terms of PCa characteristics and responses after treatment show a high level of heterogeneity of results among studies. These two ratios can represent the inflammatory and immunity status of the patient related to several conditions. A higher predictive value is related to a high NLR in terms of risk for overall mortality in metastatic PCa cases under systemic treatments.展开更多
Background:Lower urinary tract symptoms(LUTS)and pain are clinically relevant problems after transurethral resection(TURBT)of nonmuscle-invasive bladder cancer.Although intravesical instillation of hyaluronic acid has...Background:Lower urinary tract symptoms(LUTS)and pain are clinically relevant problems after transurethral resection(TURBT)of nonmuscle-invasive bladder cancer.Although intravesical instillation of hyaluronic acid has already been proven to be a valid treatment for storage LUTS and pain in patients with inflammatory bladder syndrome,its effcacy in patients who undergo TURBT is unknown.This study aimed to present the results of a prospective,randomized,controlled,clinical pilot study on the safety and clinical performance of Hydeal Cyst(Fidia Farmaceutici S.p.A.,Italy),a device formulated to provide progressive,long-lasting intravesical release of hyaluronic acid.Materials and methods:Adults diagnosed with nonmuscle-invasive bladder cancer and scheduled for TURBT were included and underwent 4 visits up to 25 days after TURBT.Of the 47 patients who completed the investigation,25 participants received 2 postoperative intravesical instillations with Hydeal Cyst.The effcacy of Hydeal Cyst on storage LUTS,pain,urinary symptoms,and patients'quality of life was evaluated using validated questionnaires.Results:Although the overall LUTS were similar in the 2 experimental groups,lower micturition frequency and fewer daytime micturitions were observed in patients treated with Hydeal Cyst.These patients also showed a signifcant reduction in pain(p=0.03)3 days after catheter removal and better quality of life at the end of the study.The device was well tolerated,with no treatment-emergent adverse events of severe intensity.Conclusion:The results from this pilot study indicate a clinically meaningful improvement of symptoms after 2 instillations of Hydeal Cyst,supporting this intervention as a potentially effective treatment for LUTS and pain after TURBT.展开更多
文摘Objective: To analyze data available in the literature regarding a possible prognostic value of the platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) in prostate cancer (PCa) patients stratified in non-metastatic and metastatic diseases.Methods: A literature search process was performed following the Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines. In our meta-analysis, the pooled event rate estimated and the pooled hazard ratio were calculated using a random effect model.Results: Forty-two articles were selected for our analysis. The pooled risk difference for non-organ confined PCa between high and low NLR cases was 0.06 (95% confidence interval [CI]: −0.03-0.15) and between high and low PLR cases increased to 0.30 (95% CI: 0.16-0.43). In non-metastatic PCa cases, the pooled hazard ratio for overall mortality between high and low NLR was 1.33 (95% CI: 0.78-1.88) and between high and low PLR was 1.47 (95% CI: 0.91-2.03), whereas in metastatic PCa cases, between high and low NLR was 1.79 (95% CI: 1.44-2.13) and between high and low PLR was 1.05 (95% CI: 0.87-1.24).Conclusion: The prognostic values of NLR and PLR in terms of PCa characteristics and responses after treatment show a high level of heterogeneity of results among studies. These two ratios can represent the inflammatory and immunity status of the patient related to several conditions. A higher predictive value is related to a high NLR in terms of risk for overall mortality in metastatic PCa cases under systemic treatments.
文摘Background:Lower urinary tract symptoms(LUTS)and pain are clinically relevant problems after transurethral resection(TURBT)of nonmuscle-invasive bladder cancer.Although intravesical instillation of hyaluronic acid has already been proven to be a valid treatment for storage LUTS and pain in patients with inflammatory bladder syndrome,its effcacy in patients who undergo TURBT is unknown.This study aimed to present the results of a prospective,randomized,controlled,clinical pilot study on the safety and clinical performance of Hydeal Cyst(Fidia Farmaceutici S.p.A.,Italy),a device formulated to provide progressive,long-lasting intravesical release of hyaluronic acid.Materials and methods:Adults diagnosed with nonmuscle-invasive bladder cancer and scheduled for TURBT were included and underwent 4 visits up to 25 days after TURBT.Of the 47 patients who completed the investigation,25 participants received 2 postoperative intravesical instillations with Hydeal Cyst.The effcacy of Hydeal Cyst on storage LUTS,pain,urinary symptoms,and patients'quality of life was evaluated using validated questionnaires.Results:Although the overall LUTS were similar in the 2 experimental groups,lower micturition frequency and fewer daytime micturitions were observed in patients treated with Hydeal Cyst.These patients also showed a signifcant reduction in pain(p=0.03)3 days after catheter removal and better quality of life at the end of the study.The device was well tolerated,with no treatment-emergent adverse events of severe intensity.Conclusion:The results from this pilot study indicate a clinically meaningful improvement of symptoms after 2 instillations of Hydeal Cyst,supporting this intervention as a potentially effective treatment for LUTS and pain after TURBT.
